| 
MechanismBacterial DNA gyrase inhibitors [+2]    | 
 | 
 | 
 | 
Inactive Indication-  | 
Drug Highest PhaseApproved  | 
First Approval Ctry. / Loc.Germany   | 
First Approval Date28 May 2020  | 
100 Clinical Results associated with Tubilux Pharma SpA
0  Patents (Medical) associated with Tubilux Pharma SpA
100 Deals associated with Tubilux Pharma SpA
100 Translational Medicine associated with Tubilux Pharma SpA